Spectral AI to Participate in 2026 British Burn Association Annual Conference

Rhea-AI Summary

Spectral AI (Nasdaq:MDAI) will participate in the 2026 British Burn Association Annual Meeting, June 17-19, 2026, in Nottingham, England. The FDA-cleared DeepView System for burn indication will be displayed at Stand #22 and featured in multiple podium and poster presentations.

The system has FDA De Novo Classification (May 2026) and initial UKCA authorization (February 2024). Spectral AI expects first commercial DeepView sales by year-end 2026.

News Market Reaction – MDAI

+1.64%

+1.64% Session close to close

In the Jun 11 session, MDAI gained 1.64%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights expanded clinical visibility for the FDA De Novo–cleared DeepView Syste...

Analysis

This announcement highlights expanded clinical visibility for the FDA De Novo–cleared DeepView System at the 2026 BBA conference, following prior showcases and awards. The device offers rapid, AI-driven burn assessment with image capture in 0.2 seconds and processing in 20–25 seconds, trained on over 340 billion pixels of data. Investors may track how conference engagement and existing UKCA authorization translate into the company’s goal of initial DeepView commercial sales by year end 2026.

Key Figures

BBA conference dates: June 17–19, 2026 Image acquisition time: 0.2 seconds AI processing time: 20–25 seconds +5 more

8 metrics

BBA conference dates June 17–19, 2026 British Burn Association Annual Meeting timing

Image acquisition time 0.2 seconds DeepView System burn wound image capture duration

AI processing time 20–25 seconds DeepView image processing and classification time

Healing assessment horizon 21 days Determines if burn areas are unlikely to heal within this period

Training data size over 340 billion pixels Burn wound image data in DeepView training database

FDA De Novo date May 2026 De Novo Classification granted for DeepView burn indication

Initial UKCA authorization February 2024 DeepView initial UKCA approval in the United Kingdom

First sales timing by year end 2026 Company expectation for first commercial DeepView sales

Previous AI Reports

5 past events · Latest: Jun 01 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 01	Annual meeting results	Positive	-1.9%	All annual meeting proposals approved and operational highlights reiterated.
May 26	Regulatory clearance	Positive	-11.6%	FDA De Novo Classification granted for DeepView burn indication.
Apr 30	Innovation award	Positive	+5.7%	Company wins Small Business Innovator Award for DeepView System.
Apr 22	Conference showcase	Positive	+4.5%	DeepView showcased at American Burn Association meeting to clinicians.
Apr 20	Annual meeting notice	Neutral	-5.3%	Announcement of date, record date, and logistics for 2026 meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-tagged news for MDAI has produced mixed reactions, with an average move of -1.73% and several positive operational updates followed by negative or muted price responses.

Recent Company History

Over the past few months, Spectral AI has issued multiple AI-related updates, including FDA De Novo clearance for DeepView, awards recognition, and showcasing the system at major burn conferences. AI-tagged releases around governance items and regulatory milestones often saw negative reactions (e.g., -11.57% on FDA clearance, -1.93% after the annual meeting), while conference and award news produced gains up to +5.67% and +4.46%. Today’s BBA conference participation continues this pattern of visibility-building announcements around DeepView.

Key Terms

de novo classification, ukca, multispectral imaging, ai algorithm

4 terms

de novo classification regulatory

"This innovative, first-of-its-kind burn wound assessment technology was granted De Novo Classification by the U.S. Food and Drug Administration"

A de novo classification is a regulatory pathway that lets a novel medical device without an existing equivalent be reviewed and approved as low-to-moderate risk so it can legally enter the market. For investors, it matters because it can unlock a faster, clearer route to sales and competition protection for a new product — like getting a brand-new grocery item its own shelf space rather than forcing it to fit an existing category.

ukca regulatory

"and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024"

A UKCA mark is a safety and regulation label used in Great Britain that shows a product meets required UK rules for health, safety and performance. For investors, the mark matters because it determines whether a product can be legally sold in the UK market, and obtaining it can affect costs, production timing and reputational risk — think of it as a passport or stamp of approval that clears goods for UK sales.

multispectral imaging medical

"combines multispectral imaging with a proprietary AI algorithm to assess the healing potential"

Multispectral imaging is a way of taking pictures that capture light across several distinct bands, including wavelengths the human eye cannot see, to reveal material properties or features hidden in ordinary photos. For investors, this technology can signal improved product capabilities, more accurate testing or monitoring, and new market opportunities or cost savings for companies that use it, making it a factor in competitive advantage and capital allocation decisions.

ai algorithm technical

"combines multispectral imaging with a proprietary AI algorithm to assess the healing potential"

A machine-learning program that digests large amounts of data to spot patterns, make predictions or carry out tasks without step-by-step human instructions — think of it as a very fast, self-tuning recipe that improves as it sees more ingredients. Investors care because these systems can change a company’s speed, accuracy and cost in areas like product development, customer service and trading, affecting growth, margins and operational risk.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company Will Showcase FDA-Cleared DeepView® System for Burn Indication

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its participation in the upcoming British Burn Association (“BBA”) Annual Meeting, being held June 17-19, 2026 at the Nottingham Trent University, Nottingham, England.   

The Company’s DeepView^® System will be on display at Stand #22 and will be the subject of multiple podium and poster presentations during the conference. This innovative, first-of-its-kind burn wound assessment technology was granted De Novo Classification by the U.S. Food and Drug Administration (“FDA”) in May 2026 and received its initial UKCA (UK Conformity Assessed) authorization in the United Kingdom in February 2024. The Company expects to generate its first commercial sales of the DeepView System by year end 2026.   

The BBA Annual Meeting is a multidisciplinary conference that brings together burn care professionals from across the UK and beyond to share clinical experience, research, and advances in burn treatment. The theme for this year’s event is “Are We There Yet? National Burn Care Review: 25 Years On.”

“We are excited to be participating in the 2026 BBA Annual Meeting so soon after being granted FDA De Novo Classification for the DeepView System,” said Vincent Capone, Chief Executive Officer. “This approval has created significant runway for enhanced long-term shareholder value. We look forward to further elevating the profile of our technology among the burn community and sharing meaningful data related to the efficacy and impact of the DeepView System in burn wound assessment.”

About the DeepView System
Spectral AI's DeepView System is a non-invasive, predictive medical device which combines multispectral imaging with a proprietary AI algorithm to assess the healing potential of areas within the burn wounds. The DeepView System provides clinicians with an immediate, data-driven assessment of whether areas within burn wounds are unlikely to heal within 21 days and may require significant medical intervention, enabling earlier and more informed treatment decisions. The image acquisition takes 0.2 seconds, and all image processing and AI model classification takes approximately 20 to 25 seconds. The DeepView System is trained and tested against a proprietary and clinically validated database of over 340 billion pixels of burn wound image data.

About Spectral AI
Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView^® System. The DeepView^® System is a predictive diagnostic device that offers physicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal to change the current standard of care, the DeepView^® System is expected to provide faster and more accurate diagnostic insight for triage and surgical planning across the burn care pathway, by improving patient outcomes and reducing healthcare costs. For more information about the DeepView^® System, visit https://www.spectral-ai.com.  

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors:
The Equity Group
Devin Sullivan	Conor Rodriguez
Managing Director	Associate
Devin.Sullivan@theequitygroup.com	Conor.Rodriguez@theequitygroup.com

FAQ

What is Spectral AI (Nasdaq:MDAI) presenting at the 2026 British Burn Association conference?

Spectral AI is showcasing its FDA-cleared DeepView System for burn indication at the 2026 British Burn Association Annual Meeting. According to Spectral AI, DeepView will be displayed at Stand #22 and highlighted in multiple podium and poster presentations to burn-care professionals.

When and where will Spectral AI (MDAI) attend the 2026 British Burn Association Annual Meeting?

Spectral AI will attend the British Burn Association Annual Meeting from June 17-19, 2026, at Nottingham Trent University, England. According to Spectral AI, the multidisciplinary event gathers burn care professionals to share clinical experience, research, and advances in burn treatment and management.

What regulatory clearances does Spectral AI's DeepView System have for burn assessment?

DeepView has FDA De Novo Classification for burn indication (May 2026) and initial UKCA authorization in the UK (February 2024). According to Spectral AI, these clearances support DeepView as a non-invasive, predictive device for assessing burn wound healing potential and guiding treatment decisions.

How does Spectral AI's DeepView System support burn wound treatment decisions?

DeepView combines multispectral imaging and AI to assess burn wound healing potential. According to Spectral AI, it indicates areas unlikely to heal within 21 days, with image capture in 0.2 seconds and AI classification in about 20-25 seconds, enabling earlier, data-driven intervention decisions for clinicians.

When does Spectral AI (MDAI) expect first commercial sales of the DeepView System?

Spectral AI expects its first commercial DeepView System sales by year-end 2026. According to Spectral AI, the FDA De Novo Classification and UKCA authorization provide a foundation to move from clinical validation toward commercialization in burn care, supporting its strategy to improve wound care diagnostics.